Skip to main content
SpringerLink
Log in

Physostigmine in Alzheimer’s Disease

  • Chapter
Cholinergic Basis for Alzheimer Therapy

Part of the book series: Advances in Alzheimer Disease Therapy ((AADT))

Abstract

Medical illnesses of the aging community in the United States are a major public health concern because of current life expectancy. In 1990, approximately 12.5% of the U.S. population was over the age of 65. By 2040 this will increase to approximately 22%. Recent community surveys indicate that as much as 10% of the over age 65 population are afflicted with Alzheimer’s disease (AD) (Evans et al. 1989), the most prevalent form of dementia. All prevalence studies indicate a marked increase in AD with aging with the proportion of individuals afflicted with this disease approximately doubling with every five-year epoch after the age of 65.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ashford JW, Soldinger S, Schaeffer J, Cochran L and Jarvik L (1981): Physostigmine and its effects on six patients with dementia. Am J Psychiatry 138:829–830.

    Google Scholar 

  • Beatty WW, Butters N and Janowsky DS (1986): Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypothesis of dementia. Behav Neural Biol 45:196–221.

    Article  Google Scholar 

  • Belier SA, Overall JE and Swann AC (1985): Efficacy of oral physostigmine in primary degenerative dementia. Psychopharmacology 147-151.

    Google Scholar 

  • Christie JE, Shering A, Ferguson J et al. (1981): Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138:46–50.

    Article  Google Scholar 

  • Davis KL and Mohs R (1982): Enhancement of memory processes in Alzheimer’s disease with multiple-dose intravenous physostigmine. Am J Psychiatry 139:1421–1424.

    Google Scholar 

  • Deutsch DA (1971): The cholinergic synapse and the site of memory. Science 174:788–794.

    Article  Google Scholar 

  • Drachman DA and Leavitt J (1974): Human memory and the cholinergic system: Relationship to aging? Arch Neurol 30:113–121.

    Article  Google Scholar 

  • DSM III (1980): Diagnostic and Statistical Manual of Mental Disorders, Third Edition, American Psychiatric Association.

    Google Scholar 

  • Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cock NR, Chown MJ, Hebert LE, Hennekins CH and Taylor JO (1989): Prevalence of Alzheimer’s disease in a community population of older persons. JAMA 262:2551–2556.

    Article  Google Scholar 

  • Harrell L, Falgout J, Leli D, Jope R McLain C, Spiers M, Callaway R and Halsey J (1986): Behavioral effects of oral physostigmine in Alzheimer’s disease patients. Neurology 36(Suppl 1):269.

    Google Scholar 

  • Jenike MA, Albert MS, Heller H, Günther J and Goff D (1990): Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer’s type: A double-blind placebo-controlled trial. J Clin Psychiatry 51:3–7.

    Google Scholar 

  • Joachim CL, Morris JH and Selkoe DJ (1988): Clinically diagnosed Alzheimer’s disease: Autopsy results in 150 cases. Ann Neurol 24:50–56.

    Article  Google Scholar 

  • Katzman R (1986): Alzheimer’s disease. N Engl J Med 15:964–973.

    Article  Google Scholar 

  • Kwo-on-Yuen PI, Mandel R, Chen A and Thal LJ (1990): Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats. Exp Neurol 108:221–228.

    Article  Google Scholar 

  • Mandel RJ and Thal LJ (1988): Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats. Psychopharmacology 96:421–425.

    Article  Google Scholar 

  • Mohs RC, Davis BM, Johns CA, Mathe AA, Greenwald BS, Horvath TB and Davis K (1985): Oral physostigmine treatment of patients with Alzheimer’s disease. Am J Psychiatry 142:28–33.

    Google Scholar 

  • Muramoto O, Sugishita M and Ando K (1984): Cholinergic system and constructional praxis: A further study of physostigmine in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 47:485–491.

    Article  Google Scholar 

  • Nordstrom O and Bartfai T (1980): Muscarinic autoreceptor regulates acetylcholine release in rat hippocampus: in vitro evidence. Acta Physiol 108:347–353.

    Article  Google Scholar 

  • Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH and Perry RH (1978): Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457–1459.

    Article  Google Scholar 

  • Peters BH and Levin HS (1977): Memory enhancement after physostigmine treatment in the amnesic syndrome. Arch Neural 34:215–219.

    Article  Google Scholar 

  • Peters B and Levin HS (1979): Effects of physostigmine and lecithin on memory in Alzheimer’s disease. Ann Neurol 6:219–221.

    Article  Google Scholar 

  • Ron MA, Toone BK, Garralda ME et al. (1979): Diagnostic accuracy in presenile dementia. Br J Psychiatry 134:161–168.

    Article  Google Scholar 

  • Sano M, Stern Y, Strides L, Marder K and Mayeux R (1988): Physostigmine response in probable Alzheimer’s disease is related to duration of exposure. Neurology 38 (Suppl 1):373.

    Google Scholar 

  • Schwartz AS and Kohlstaedt EV (1986): Physostigmine effects in Alzheimer’s disease: Relationship to dementia severity. Life Sci 38:1021–1028.

    Article  Google Scholar 

  • Selkoe DJ (1990): Deciphering Alzheimer’s disease: The amyloid precursor protein yields new clues. Science 248:1058–1060.

    Article  Google Scholar 

  • Sharpless NS and Thal LJ (1985): Plasma physostigmine concentrations after oral administration. Lancet 1:1397–1398.

    Article  Google Scholar 

  • Stern Y, Sano M and Mayeux R (1987): Effects of oral physostigmine in Alzheimer’s disease. Ann Neurol 22:306–310.

    Article  Google Scholar 

  • Terry RD and Katzman R (1983): Senile dementia of the Alzheimer type. Ann Neurol 14:497–506.

    Article  Google Scholar 

  • Thal LJ, Fuld PA, Masur DM and Sharpless NS (1983): Oral physostigmine and lecithin improve memory in Alzheimer’s disease. Ann Neurol 13:491–496.

    Article  Google Scholar 

  • Thal LJ Masur DM, Blau AD, Fuld PA and Klauber MR (1989): Chronic oral physostigmine without lecithin improves memory in Alzheimer’s disease. J Am Geriatr Soc 37:42–48.

    Google Scholar 

  • Thal LJ, Lasker B, Sharpless NS, Bobotas G, Schor JM and Nigalye A (1989): Plasma physostigmine concentrations after controlled-release oral administration. Arch Neurol 46:13.

    Google Scholar 

  • Wade JP, Mirsen TR, Hachinski VC, Fisman M, Lau C and Merskey H (1987): The clinical diagnosis of Alzheimer’s disease. Arch Neurol 44:24–29.

    Article  Google Scholar 

  • Wettstein A (1983): No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Ann Neurol 13:210–212.

    Article  Google Scholar 

  • Whitehouse PJ, Price DL, Clark AW, Coyle JT and DeLong MR (1981): Alzheimer’s disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122–126.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosciences, University of California, San Diego, USA

    Leon J. Thal

  2. Neurology Service, Veterans Affairs Medical Center, San Diego, California, USA

    Leon J. Thal

Authors
  1. Leon J. Thal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry School of Medicine, Southern Illinois University, Springfield, IL, 62794, USA

    Robert Becker

  2. Department of Pharmacology School of Medicine, Southern Illinois University, Springfield, IL, 62794, USA

    Ezio Giacobini

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

Thal, L.J. (1991). Physostigmine in Alzheimer’s Disease. In: Becker, R., Giacobini, E. (eds) Cholinergic Basis for Alzheimer Therapy. Advances in Alzheimer Disease Therapy. Birkhäuser, Boston, MA. https://doi.org/10.1007/978-1-4899-6738-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-6738-1_24

  • Publisher Name: Birkhäuser, Boston, MA

  • Print ISBN: 978-1-4899-6740-4

  • Online ISBN: 978-1-4899-6738-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation